Oppenheimer assumed coverage of Abeona Therapeutics (ABEO) with an Outperform rating and $19 price target The firm notes Abeona’s Q1 update highlighted strong early momentum following ZEVASKYN’s April approval. The first Qualified Treatment Center has been activated ahead of schedule with the first patient on track for treatment in Q3 2025. Enthusiasm from patients/caregivers and physicians remains high. Notably, management highlighted strong interest at the SID conference, Oppenheimer adds. Based on the early launch progress, the firm’s confidence in ZEVASKYN’s commercial trajectory is reaffirmed.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- Abeona Therapeutics Elects New Directors at Meeting
- Abeona Therapeutics: Strong Product Launch and Financial Position Justify Buy Rating
- Abeona Therapeutics Reports Improved Financial Performance
- Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue